| Literature DB >> 33176769 |
Chun-Hsuan Lin1, Wen-Jeng Wu1,2,3, Ching-Chia Li1,2,3, Sheng-Chen Wen4,5,6.
Abstract
BACKGROUND: To evaluate preoperative predictors of enucleation time during en bloc 'no-touch' holmium laser enucleation of the prostate (HoLEP)Entities:
Keywords: Benign prostatic hyperplasia; En bloc ‘no-touch’ enucleation; Enucleation time; Holmium laser enucleation of the prostate; Preoperative predictors
Mesh:
Year: 2020 PMID: 33176769 PMCID: PMC7661272 DOI: 10.1186/s12894-020-00758-4
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Characteristic of patients undergoing HoLEP
| Characteristic | Data |
|---|---|
| Total patients, n | 135 |
| Age (year), mean (SD) | 71.7 (9.3) |
| History of 5ARi use, n (%) | 21 (16) |
| Requiring Foley catheter at the time of HoLEP, n (%) | 14 (10.3) |
| History of UTI, n (%) | 12 (9) |
| History of anticoagulation, n (%) | 13 (10) |
| Pre-HoLEP PSA (ng/mL), mean (range) | 6.2 (0.07–1380) |
| Previous TURP, n (%) | 12 (9) |
| TRUS-P volume (g), mean (SD) | 71.1 (42.8) |
| < 50 ml, n (%) | 51 (37.7) |
| 50–80 ml, n (%) | 51 (37.7) |
| > 80 ml, n (%) | 33 (24.4) |
5ARi 5-alpha-reductase inhibitor, HoLEP holmium laser enucleation of the prostate, PSA prostate-specific antigen, SD standard deviation, TRUS-P transrectal ultrasound of the prostate, UTI urinary tract infection
Enucleation-associated variables
| Variable | Value |
|---|---|
| Enucleation time (min), mean (range) | 46.1 (12–220) |
| Morcellation time (min), mean (range) | 13.3 (4–130) |
| Overall operation time (min), mean (range) | 71 (18–250) |
| Enucleation efficiency (g/min), mean (SD) | 0.9 (0.8) |
| Morcellation efficiency (g/min), mean (SD) | 4.4 (2.6) |
| Overall operation efficiency (g/min), mean (SD) | 0.5 (0.3) |
| HoLEP specimen weight (g) | |
| < 15 g, n (%) | 38 (28.2) |
| 15–50 g, n (%) | 63 (47) |
| 50–80 g, n (%) | 16 (11.7) |
| > 80 g, n (%) | 18 (12.9) |
| Beach ball identified, n (%) | 19 (14) |
| Presence of prostate cancer, n (%) | 9 (6.6) |
Fig. 1a Comparison of enucleation efficiency of HoLEP and specimen weight. b Comparison of enucleation efficiency of HoLEP and prostate volume. *The 2 parallel lines was 95% CI
Predictors of enucleation time from multiple linear regression model
| Characteristic | Coefficient (min) | 95% CI | |
|---|---|---|---|
| History of UTI | 24.23 | 2.48–45.97 | .023 |
| History of antiplatelet agents | 19.51 | − 3.16 to 42.19 | .021 |
| HoLEP specimen weight | |||
| < 15 g | Reference | ||
| 15–50 g | 17.28 | 1.01–33.56 | .024 |
| 50–80 g | 36.37 | 8.33–64.4 | .012 |
| > 80 g | 80.97 | 50.66–111.29 | < .001 |
| Constant | 18.34 | 4.25–32.43 | .011 |
Other abbreviations as in Table 1. Interpretation of linear regression model: for a patient with a history of UTI and antiplatelet agents, who had a HoLEP specimen weight of 35 g, the estimated enucleation time is 79.36 min (24.23 + 19.51 + 17.28 + 18.34 = 79.36)
CI confidence interval
Detailed analysis of Clavien grade 1–3b complication within the 30-day perioperative period
| Complication | Treatment | HoLEP (n = 135) |
|---|---|---|
| Clavien grade 1 (n = 11; 8.1%) | ||
| Urinary retention after catheter removal | Bedside recatheterization | 2 (1.5) |
| Clot retention without surgical revision | Tamponade evacuation through catheter | 9 (6.7) |
| Clavien grade 2 (n = 3; 2.2%) | ||
| Postoperative hematuria | Transfusion | 3 (2.2) |
| Clavien grade 3b (n = 1; 0.7%) | ||
| Postoperative hemorrhage | Coagulation of prostate fossa | 1 (0.7) |